Breaking News, Trials & Filings

Trials & Filings in Brief: Sept. 30, 2013

AcelRx, Alnylam, Astellas, Cardiome, DiaMedica, Halozyme, Immunomedics, Lion Biotech, Omeros, Tesaro, USB, Vertex

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I DiaMedica diabetes treatment hits primary endpoints . . . read more Halozyme gets positive PFS, OS results for PEGPH20 . . . read more Immunomedics updates ADC results in metastatic colorectal cancer . . . read more Tesaro begins dose-finding study of rolapitant . . . read more Phase II Alnylam completes Phase II enrollment for ATTR . . . read more Lion’s metastatic melanoma treatment posts positive Phase II results . . . read more Phase III Astellas posts positive aspergillo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters